Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S (Copenhagen:GEN) announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

A total of 38 patients were included in the trial, of which 12 patients received placebo and 26 patients received ofatumumab intravenously. Patients were treated with ofatumumab at the dose levels of 100 mg, 300 mg or 700 mg and followed for 24 weeks. There were no dose limiting toxicities, no unexpected safety findings and the rates of infection were comparable between the groups. Efficacy was assessed as a secondary endpoint. Although the study included a small number of patients, statistically significant reductions in the number of brain lesions (gadolinium-enhancing T1 lesions and new/enlarging T2 lesions) as measured on serial MRI scans from week 8 to week 24 were seen on ofatumumab as compared to placebo and the reductions were seen in all dose groups.

"We are encouraged by the first results from this initial Phase II study of ofatumumab in RRMS, and are looking forward to seeing the full study results later this year," said Prof. Jan G.J. van de Winkel, Ph.D., Chief Executive Officer of Genmab.